Abstract
Previous studies have found higher levels of serum malondialdehyde (MDA) in hepatocellular carcinoma (HCC) patients compared to healthy controls and higher MDA concentrations in tumoral tissue of HCC patients than in non-tumoral tissue. However, the association between pre-transplant serum levels of MDA and survival in HCC patients after liver transplantation (LT) has not been described, and the aim of the present study was to determine whether such an association exists. In this observational study we measured serum MDA levels in 127 patients before LT. We found higher pre-LT serum MDA levels in 15 non-surviving than in 112 surviving patients one year after LT (p = 0.02). Exact binary logistic regression analysis revealed that pre-LT serum levels of MDA over 3.37 nmol/mL were associated with mortality after one year of LT (Odds ratio = 5.38; 95% confidence interval (CI) = from 1.580 to infinite; p = 0.007) adjusting for age of the deceased donor. The main finding of our study was that there is an association between serum MDA levels before LT for HCC and 1-year survival after LT.
Highlights
Hepatocellular carcinoma (HCC) is the most frequent primary malignancy in the liver, one of the most frequent malignancies and the second most frequent cause of cancer-related death in the world.Globally, there are approximately 600,000 new diagnoses of hepatocellular carcinoma (HCC) each year and 750,000 deaths due to HCC
There were no significant differences after liver transplantation (LT) for HCC than in healthy controls (p < 0.001, Figure 1)
We found no differences between non-survivors and survivors regarding sex, age of LT recipients, ABO blood type, Child-Pugh score, model for end-stage liver disease (MELD)
Summary
Hepatocellular carcinoma (HCC) is the most frequent primary malignancy in the liver, one of the most frequent malignancies and the second most frequent cause of cancer-related death in the world. There are approximately 600,000 new diagnoses of HCC each year and 750,000 deaths due to HCC. Liver transplantation (LT) is generally considered the treatment of choice for selected HCC patients since the primary tumor is removed and liver failure is treated [1,2,3,4,5,6,7,8,9,10].
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call